Reported 2 days ago
Merck & Co., Inc. (MRK) stands out as an innovative biopharmaceutical company amidst rising U.S. healthcare costs, which increased by 7.5% in 2023. Factors like tariffs and reliance on Chinese manufacturing are affecting the industry's growth as it anticipates a surge in EBITDA from $676 billion in 2023 to $987 billion by 2028. Despite certain setbacks, such as pausing the Gardasil vaccine distribution in China, Merck's portfolio, including the successful cancer treatment Keytruda, continues to perform well, prompting analysts to view it as a potential investment opportunity.
Source: YAHOO